Ketabforoush, Arsh
Faghihi, Faezeh
Azedi, Fereshteh
Ariaei, Armin
Habibi, Mohamad Amin
Khalili, Maryam
Ashtiani, Bahram Haghi
Joghataei, Mohammad Taghi
Arnold, W. David http://orcid.org/0000-0001-9889-7036
Funding for this research was provided by:
Missouri Spinal Cord Injury/Disease Research Program
Article History
Accepted: 26 May 2024
First Online: 23 June 2024
Declarations
:
: WDA: Research Funding from NMD Pharma and Avidity Biosciences, Consulting for NMD Pharma, Avidity Biosciences, Dyne Therapeutics, Novartis, Design Therapeutics, Catalyst Pharmaceuticals, Novartis. Other authors claim that there are no conflicts of interest.
: All data reviewed are included in the manuscript.
: AK and WDA participated in the review conception and design. Rest of authors equally contributed to preparing this manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: AK: Research funding from the Missouri Spinal Cord Injury Disease Research Program.